• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025

    Net income of $128 million; Adjusted EBITDA of $318 million in 2025

    Subscribers grew to over 2.5 million, up 13% year-over-year in 2025

    Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com.

    "More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we're well on our way to becoming the global leader in consumer health," said Andrew Dudum, co-founder and CEO. "In 2025, we made it possible for more customers across the world to depend on us for access to care across an expanding range of conditions. From launching hormone therapies and diagnostics, introducing Labs to unlock deeper health insights, and taking meaningful steps to grow internationally, the investments we're making today position us to set a new standard in healthcare for people everywhere. The continued growth and diversification of our platform is helping to create a world where proactive, preventative, and personalized care can feel like a luxury without actually costing like one."

    "Our financial results in 2025 demonstrate the power of scaling a deeply personalized consumer health platform," said Yemi Okupe, Chief Financial Officer. "Revenue grew 59% year-over-year to $2.35 billion as we expanded our subscriber base and increased engagement across specialties by bringing new sources of value to millions of customers. With a strong balance sheet and robust operating cash flow from tenured specialties in our domestic operations, we have the flexibility to invest in scaling new specialties, advancing our technology and infrastructure, and expanding internationally, all supporting our path toward our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA."

    Key Business Metrics

    (In Thousands, Except for Monthly Revenue per Average Subscriber and Monthly Online Revenue per Average Subscriber, Unaudited)

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Subscribers (end of period)

     

     

    2,511

     

     

    2,229

     

    13

    %

     

     

    2,511

     

     

    2,229

     

    13

    %

    Monthly Revenue per Average Subscriber

     

    $

    83

     

    $

    75

     

    11

    %

     

    $

    83

     

    $

    65

     

    28

    %

    Monthly Online Revenue per Average Subscriber

     

    $

    82

     

    $

    73

     

    12

    %

     

    $

    81

     

    $

    64

     

    27

    %

    _______________

    1 Our first quarter and full year 2026 outlook: (1) excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals, and (2) assumes the ongoing ability to provide access to compounded semaglutide through our platform, and no changes to our current business relationships.

    Revenue

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    United States Revenue

     

    $

    554,147

     

    $

    474,259

     

    17

    %

     

    $

    2,213,648

     

    $

    1,449,671

     

    53

    %

    Rest of the World Revenue

     

     

    63,671

     

     

    6,880

     

    825

    %

     

     

    133,989

     

     

    26,843

     

    399

    %

    Total revenue

     

    $

    617,818

     

    $

    481,139

     

    28

    %

     

    $

    2,347,637

     

    $

    1,476,514

     

    59

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Online Revenue

     

    $

    609,113

     

    $

    470,760

     

    29

    %

     

    $

    2,311,449

     

    $

    1,437,937

     

    61

    %

    Wholesale Revenue

     

     

    8,705

     

     

    10,379

     

    (16

    )%

     

     

    36,188

     

     

    38,577

     

    (6

    )%

    Total revenue

     

    $

    617,818

     

    $

    481,139

     

    28

    %

     

    $

    2,347,637

     

    $

    1,476,514

     

    59

    %

    Fourth Quarter 2025 Financial Highlights

    • Revenue was $617.8 million for the fourth quarter of 2025 compared to $481.1 million for the fourth quarter of 2024, an increase of 28% year-over-year.
    • Gross margin was 72% for the fourth quarter of 2025 compared to 77% for the fourth quarter of 2024.
    • Net income was $20.6 million for the fourth quarter of 2025 compared to $26.0 million for the fourth quarter of 2024.
    • Adjusted EBITDA was $66.3 million for the fourth quarter of 2025 compared to $54.1 million for the fourth quarter of 2024.
    • Net cash provided by operating activities was $61.3 million for the fourth quarter of 2025 compared to $86.4 million for the fourth quarter of 2024.
    • Free Cash Flow was $(2.6) million for the fourth quarter of 2025 compared to $59.5 million for the fourth quarter of 2024.

    Full Year 2025 Financial Highlights

    • Revenue was $2,347.6 million for the year ended December 31, 2025 compared to $1,476.5 million for the year ended December 31, 2024, an increase of 59% year-over-year.
    • Gross margin was 74% for the year ended December 31, 2025 compared to 79% for the year ended December 31, 2024.
    • Net income was $128.4 million for the year ended December 31, 2025, compared to $126.0 million for the year ended December 31, 2024, which was impacted by the change in valuation allowance of $68.0 million due to the release of the valuation allowance on our domestic deferred tax assets, partially offset by tax activity for that period.
    • Adjusted EBITDA was $318.0 million for the year ended December 31, 2025 compared to $176.9 million for the year ended December 31, 2024.
    • Net cash provided by operating activities was $300.0 million for the year ended December 31, 2025 compared to $251.1 million for the year ended December 31, 2024.
    • Free Cash Flow was $57.4 million for the year ended December 31, 2025 compared to $198.3 million for the year ended December 31, 2024.

    Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States ("U.S. GAAP"), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading "Non-GAAP Financial Measures".

    Financial Outlook2

    Hims & Hers is providing the following guidance:

    For the first quarter 2026, we expect:

    • Revenue of $600 million to $625 million.
    • Adjusted EBITDA of $35 million to $55 million, reflecting an Adjusted EBITDA margin of 6% to 9%.

    For the full year 2026, we expect:

    • Revenue of $2.7 billion to $2.9 billion.
    • Adjusted EBITDA of $300 million to $375 million, reflecting an Adjusted EBITDA margin of 11% to 13%.

    The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

    Conference Call

    Hims & Hers will host a conference call to review the fourth quarter and full year 2025 results on February 23, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

    For more information, please visit investors.hims.com.

    _______________

    2 Our first quarter and full year 2026 outlook: (i) excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals, and (ii) assumes the ongoing ability to provide access to compounded semaglutide through our platform, and no changes to our current business relationships.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "assumes," "may," "will," "likely," "potential," "projects," "predicts," "continue," "goal," "strategy," "future," "forecast," "target," "outlook," "opportunity," "confidence," "foundation," "groundwork," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, and the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions; the success of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the "Commission").

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of February 23, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

    Key Business Metrics

    We continually and strategically review our key business metrics to ensure that they are helpful in managing or monitoring the performance of our business as it grows, which may result in changes in our key business metrics over time. Historically, we have disaggregated our total revenue between Online Revenue and Wholesale Revenue (both defined below). During 2025, as a result of completed acquisitions, we launched operations in the European Union and Canada, and deepened our presence in the United Kingdom. We expect to continue to expand internationally, including in connection with our proposed acquisition of Eucalyptus. As a result, we are now disaggregating our total revenue between United States Revenue and Rest of the World Revenue (both defined below). Online Revenue and Wholesale Revenue have become a less relevant disaggregation of our total revenue, and we anticipate no longer reporting these financial results beginning with the three months ending March 31, 2026. Additionally, Monthly Online Revenue per Average Subscriber (as defined below) has become less relevant for our business. We anticipate no longer reporting this metric beginning with the three months ending March 31, 2026, and are instead reporting Monthly Revenue per Average Subscriber, as defined below.

    "United States Revenue" represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

    "Rest of the World Revenue" represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

    "Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. Online Revenue also includes sales from customers who have made one-time purchases.

    "Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

    "Subscribers" are customers who have one or more "Subscriptions" pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

    "Monthly Revenue per Average Subscriber" is defined as total revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. "Average Subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

    "Monthly Online Revenue per Average Subscriber" is defined as Online Revenue divided by Average Subscribers, which amount is then further divided by the number of months in a period.

    CONSOLIDATED BALANCE SHEETS

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

    December 31,

     

    2025

     

    2024

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    228,616

     

     

    $

    220,584

     

    Short-term available-for-sale investments

     

    348,876

     

     

     

    79,667

     

    Inventory

     

    80,128

     

     

     

    64,427

     

    Prepaid expenses and other current assets

     

    110,018

     

     

     

    31,153

     

    Total current assets

     

    767,638

     

     

     

    395,831

     

    Restricted cash

     

    —

     

     

     

    856

     

    Long-term available-for-sale investments

     

    351,263

     

     

     

    —

     

    Goodwill

     

    278,325

     

     

     

    112,728

     

    Property, equipment, and software, net

     

    311,930

     

     

     

    82,083

     

    Intangible assets, net

     

    196,116

     

     

     

    43,410

     

    Operating lease right-of-use assets

     

    137,046

     

     

     

    10,881

     

    Deferred tax assets, net

     

    82,707

     

     

     

    61,603

     

    Other long-term assets

     

    29,680

     

     

     

    147

     

    Total assets

    $

    2,154,705

     

     

    $

    707,539

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    143,278

     

     

    $

    91,180

     

    Accrued liabilities

     

    78,518

     

     

     

    53,013

     

    Deferred revenue

     

    127,160

     

     

     

    75,285

     

    Earn-out payable

     

    46,986

     

     

     

    —

     

    Earn-out liabilities

     

    3,646

     

     

     

    —

     

    Operating lease liabilities

     

    4,843

     

     

     

    1,889

     

    Total current liabilities

     

    404,431

     

     

     

    221,367

     

    Convertible senior notes, net

     

    972,580

     

     

     

    —

     

    Operating lease liabilities

     

    143,167

     

     

     

    9,456

     

    Earn-out liabilities

     

    53,009

     

     

     

    —

     

    Deferred tax liabilities, net

     

    28,856

     

     

     

    —

     

    Other long-term liabilities

     

    11,734

     

     

     

    —

     

    Total liabilities

     

    1,613,777

     

     

     

    230,823

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 218,867,898 and 212,459,586 shares issued and outstanding as of December 31, 2025 and 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2025 and 2024

     

    23

     

     

     

    22

     

    Additional paid-in capital

     

    652,383

     

     

     

    719,155

     

    Accumulated other comprehensive income (loss)

     

    2,294

     

     

     

    (324

    )

    Accumulated deficit

     

    (113,772

    )

     

     

    (242,137

    )

    Total stockholders' equity

     

    540,928

     

     

     

    476,716

     

    Total liabilities and stockholders' equity

    $

    2,154,705

     

     

    $

    707,539

     

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Revenue

     

    $

    617,818

     

     

    $

    481,139

     

     

    $

    2,347,637

     

     

    $

    1,476,514

     

    Cost of revenue

     

     

    173,383

     

     

     

    111,598

     

     

     

    614,259

     

     

     

    303,379

     

    Gross profit

     

     

    444,435

     

     

     

    369,541

     

     

     

    1,733,378

     

     

     

    1,173,135

     

    Gross margin %

     

     

    72

    %

     

     

    77

    %

     

     

    74

    %

     

     

    79

    %

    Operating expenses:(1)

     

     

     

     

     

     

     

     

    Marketing

     

     

    238,049

     

     

     

    221,085

     

     

     

    919,296

     

     

     

    678,844

     

    Operations and support

     

     

    80,073

     

     

     

    58,083

     

     

     

    286,444

     

     

     

    185,802

     

    Technology and development

     

     

    40,962

     

     

     

    23,749

     

     

     

    149,301

     

     

     

    78,819

     

    General and administrative

     

     

    76,165

     

     

     

    48,028

     

     

     

    272,724

     

     

     

    167,767

     

    Total operating expenses

     

     

    435,249

     

     

     

    350,945

     

     

     

    1,627,765

     

     

     

    1,111,232

     

    Income from operations

     

     

    9,186

     

     

     

    18,596

     

     

     

    105,613

     

     

     

    61,903

     

    Other income (expense):

     

     

     

     

     

     

     

     

    Change in fair value of equity securities

     

     

    4,437

     

     

     

    —

     

     

     

    4,437

     

     

     

    —

     

    Change in fair value of liabilities

     

     

    (1,629

    )

     

     

    —

     

     

     

    (9,255

    )

     

     

    —

     

    Other income, net

     

     

    6,359

     

     

     

    3,695

     

     

     

    23,129

     

     

     

    9,808

     

    Total other income, net

     

     

    9,167

     

     

     

    3,695

     

     

     

    18,311

     

     

     

    9,808

     

    Income before income taxes

     

     

    18,353

     

     

     

    22,291

     

     

     

    123,924

     

     

     

    71,711

     

    Benefit from income taxes

     

     

    2,248

     

     

     

    3,734

     

     

     

    4,441

     

     

     

    54,327

     

    Net income

     

     

    20,601

     

     

     

    26,025

     

     

     

    128,365

     

     

     

    126,038

     

    Other comprehensive income (loss)

     

     

    1,373

     

     

     

    (553

    )

     

     

    2,618

     

     

     

    (200

    )

    Total comprehensive income

     

    $

    21,974

     

     

    $

    25,472

     

     

    $

    130,983

     

     

    $

    125,838

     

     

     

     

     

     

     

     

     

     

    Net income per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.09

     

     

    $

    0.12

     

     

    $

    0.57

     

     

    $

    0.58

     

    Diluted

     

    $

    0.08

     

     

    $

    0.11

     

     

    $

    0.51

     

     

    $

    0.53

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

     

    Basic

     

     

    227,056,624

     

     

     

    219,027,485

     

     

     

    224,959,268

     

     

     

    215,939,037

     

    Diluted

     

     

    248,096,429

     

     

     

    240,725,350

     

     

     

    258,230,547

     

     

     

    236,808,876

     

    ______________

    (1)

    Includes stock-based compensation expense as follows (in thousands):

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Marketing

     

    $

    3,185

     

     

    $

    2,637

     

     

    $

    12,510

     

     

    $

    9,392

     

    Operations and support

     

     

    5,873

     

     

    2,743

     

     

    18,910

     

     

    10,205

    Technology and development

     

     

    5,106

     

     

     

    3,824

     

     

     

    19,240

     

     

     

    12,534

     

    General and administrative

     

     

    20,324

     

     

     

    15,145

     

     

     

    84,584

     

     

     

    60,191

     

    Total stock-based compensation expense

     

    $

    34,488

     

     

    $

    24,349

     

     

    $

    135,244

     

     

    $

    92,322

     

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In Thousands, Unaudited)

     

     

    Years Ended December 31,

     

    2025

     

    2024

    Operating activities

     

     

     

    Net income

    $

    128,365

     

     

    $

    126,038

     

    Adjustments to reconcile net income to net cash provided by operating activities

     

     

     

    Depreciation and amortization

     

    54,502

     

     

     

    17,088

     

    Stock-based compensation

     

    135,244

     

     

     

    92,322

     

    Change in fair value of equity securities

     

    (4,437

    )

     

     

    —

     

    Change in fair value of liabilities

     

    9,255

     

     

     

    —

     

    Net accretion on securities

     

    (2,032

    )

     

     

    (4,355

    )

    Benefit from deferred taxes

     

    (12,961

    )

     

     

    (61,649

    )

    Impairment of long-lived assets

     

    531

     

     

     

    114

     

    Amortization of debt discount and issuance costs

     

    4,529

     

     

     

    —

     

    Non-cash operating lease cost

     

    12,413

     

     

     

    2,546

     

    Non-cash acquisition-related costs

     

    5,893

     

     

     

    —

     

    Non-cash other

     

    (2,135

    )

     

     

    357

     

    Changes in operating assets and liabilities:

     

     

     

    Inventory

     

    (13,722

    )

     

     

    (41,612

    )

    Prepaid expenses and other current assets

     

    (51,856

    )

     

     

    (9,494

    )

    Other long-term assets

     

    (518

    )

     

     

    (56

    )

    Accounts payable

     

    30,297

     

     

     

    43,710

     

    Accrued liabilities

     

    (43,053

    )

     

     

    23,791

     

    Deferred revenue

     

    51,604

     

     

     

    67,552

     

    Operating lease liabilities

     

    (1,913

    )

     

     

    (2,443

    )

    Earn-out payable

     

    —

     

     

     

    (2,825

    )

    Net cash provided by operating activities

     

    300,006

     

     

     

    251,084

     

    Investing activities

     

     

     

    Purchases of available-for-sale investments

     

    (725,838

    )

     

     

    (160,564

    )

    Maturities of available-for-sale investments

     

    108,698

     

     

     

    208,940

     

    Proceeds from sales of available-for-sale investments

     

    —

     

     

     

    725

     

    Investment in website development and internal-use software

     

    (16,546

    )

     

     

    (11,095

    )

    Purchases of property, equipment, and intangible assets

     

    (226,045

    )

     

     

    (41,655

    )

    Acquisition of businesses, net of cash acquired

     

    (145,227

    )

     

     

    (15,399

    )

    Purchase of equity securities

     

    (20,000

    )

     

     

    —

     

    Net cash used in investing activities

     

    (1,024,958

    )

     

     

    (19,048

    )

    Financing activities

     

     

     

    Proceeds from issuance of convertible senior notes, net of debt discount

     

    970,000

     

     

     

    —

     

    Purchases of capped calls related to convertible senior notes

     

    (47,800

    )

     

     

    —

     

    Proceeds from exercise of vested stock options

     

    11,033

     

     

     

    26,651

     

    Payments for taxes related to net share settlement of equity awards

     

    (116,669

    )

     

     

    (52,501

    )

    Repurchases of common stock

     

    (89,960

    )

     

     

    (83,039

    )

    Proceeds from employee stock purchase plan

     

    6,440

     

     

     

    3,901

     

    Payments for debt issuance costs

     

    (3,424

    )

     

     

    —

     

    Payments for acquisition-related earn-out consideration

     

    —

     

     

     

    (3,190

    )

    Proceeds from exercise of Class A common stock warrants

     

    —

     

     

     

    333

     

    Net cash provided by (used in) financing activities

     

    729,620

     

     

     

    (107,845

    )

    Foreign currency effect on cash and cash equivalents

     

    2,508

     

     

     

    (270

    )

    Increase in cash, cash equivalents, and restricted cash

     

    7,176

     

     

     

    123,921

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    221,440

     

     

     

    97,519

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    228,616

     

     

    $

    221,440

     

    Reconciliation of cash, cash equivalents, and restricted cash

     

     

     

    Cash and cash equivalents

    $

    228,616

     

     

    $

    220,584

     

    Restricted cash

     

    —

     

     

     

    856

     

    Total cash, cash equivalents, and restricted cash

    $

    228,616

     

     

    $

    221,440

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes

    $

    23,162

     

     

    $

    7,916

     

    Non-cash investing and financing activities

     

     

     

    Purchases of property and equipment included in accounts payable and accrued liabilities

    $

    25,244

     

     

    $

    7,781

     

    Right-of-use asset obtained in exchange for lease liability

     

    132,837

     

     

     

    2,593

     

    Issuance of common stock in connection with asset acquisition

     

    12,760

     

     

     

    —

     

    Common stock to be issued for asset acquisition indemnification holdback

     

    6,380

     

     

     

    —

     

    Common stock issued, contingent consideration, additional consideration payable, and liabilities assumed in connection with acquisition of businesses

     

    200,267

     

     

     

    16,000

     

    Issuance of common stock for acquisition-related earn-out consideration

     

    —

     

     

     

    1,396

     

    Non-GAAP Financial Measures

    In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

    However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

    Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net income before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), change in fair value of liabilities, payroll tax expense related to stock-based compensation, impairment of long-lived assets, legal settlement expenses that are considered non-recurring, change in fair value of equity securities, income taxes, and interest income and expense, net. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

    In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

    Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income and other U.S. GAAP results.

    Net Income to Adjusted EBITDA Reconciliation

    (In Thousands, Unaudited)

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

    2025

     

    2024

     

    2025

     

    2024

     

     

     

     

     

     

     

     

    Revenue

    $

    617,818

     

     

    $

    481,139

     

     

    $

    2,347,637

     

     

    $

    1,476,514

     

     

     

     

     

     

     

     

     

    Net income

     

    20,601

     

     

     

    26,025

     

     

     

    128,365

     

     

     

    126,038

     

    Stock-based compensation

     

    34,488

     

     

     

    24,349

     

     

     

    135,244

     

     

     

    92,322

     

    Depreciation and amortization

     

    18,092

     

     

     

    6,061

     

     

     

    54,502

     

     

     

    17,088

     

    Acquisition and transaction-related costs

     

    3,451

     

     

     

    2,155

     

     

     

    15,544

     

     

     

    3,979

     

    Change in fair value of liabilities

     

    1,629

     

     

     

    —

     

     

     

    9,255

     

     

     

    —

     

    Payroll tax expense related to stock-based compensation

     

    1,555

     

     

     

    —

     

     

     

    6,947

     

     

     

    —

     

    Legal settlement

     

    —

     

     

     

    2,008

     

     

     

    —

     

     

     

    2,008

     

    Impairment of long-lived assets

     

    —

     

     

     

    —

     

     

     

    531

     

     

     

    114

     

    Benefit from income taxes

     

    (2,248

    )

     

     

    (3,734

    )

     

     

    (4,441

    )

     

     

    (54,327

    )

    Change in fair value of equity securities

     

    (4,437

    )

     

     

    —

     

     

     

    (4,437

    )

     

     

    —

     

    Interest income and expense, net

     

    (6,805

    )

     

     

    (2,741

    )

     

     

    (23,526

    )

     

     

    (10,349

    )

    Adjusted EBITDA

    $

    66,326

     

     

    $

    54,123

     

     

    $

    317,984

     

     

    $

    176,873

     

     

     

     

     

     

     

     

     

    Net income as a % of revenue

     

    3

    %

     

     

    5

    %

     

     

    5

    %

     

     

    9

    %

    Adjusted EBITDA margin

     

    11

    %

     

     

    11

    %

     

     

    14

    %

     

     

    12

    %

    Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. "Free Cash Flow" is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

    Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.

    Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Net cash provided by operating activities

     

    $

    61,312

     

     

    $

    86,385

     

     

    $

    300,006

     

     

    $

    251,084

     

    Less: purchases of property, equipment, and intangible assets in investing activities

     

     

    (59,388

    )

     

     

    (24,520

    )

     

     

    (226,045

    )

     

     

    (41,655

    )

    Less: investment in website development and internal-use software in investing activities

     

     

    (4,493

    )

     

     

    (2,365

    )

     

     

    (16,546

    )

     

     

    (11,095

    )

    Free Cash Flow

     

    $

    (2,569

    )

     

    $

    59,500

     

     

    $

    57,415

     

     

    $

    198,334

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260223564900/en/

    Investor Relations

    Bill Newby

    [email protected]

    Media Relations

    Abby Reisinger-Moley

    [email protected]

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    More analyst ratings

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 5,262 shares at a strike of $5.01 and sold $139,108 worth of shares (5,262 units at $26.44) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    2/4/26 4:13:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 9,067 shares at a strike of $6.27 and sold $275,114 worth of shares (9,067 units at $30.34) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/21/26 4:23:35 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 5,986 shares at a strike of $9.16 and sold $306,453 worth of shares (9,070 units at $33.79), decreasing direct ownership by 3% to 91,617 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/7/26 4:16:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    KeyBanc Capital Markets initiated coverage on Hims & Hers Health

    KeyBanc Capital Markets initiated coverage of Hims & Hers Health with a rating of Sector Weight

    10/21/25 7:20:02 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

    San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you. Purpose and Scope This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss

    2/5/26 8:51:30 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form 10-K filed by Hims & Hers Health Inc.

    10-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/23/26 5:20:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/23/26 4:07:25 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/19/26 6:19:32 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care